

17. The recombinant AAV according to claim 16, wherein the minigene comprises a promoter.

18. The recombinant AAV according to claim 17, wherein the promoter is an inducible promoter.

19. The recombinant AAV according to claim 17, wherein the promoter is a constitutive promoter.

20. The recombinant AAV according to claim 19, wherein the promoter is selected from the cytomegalovirus immediate early promoter and the Rous sarcoma virus LTR promoter.

21. A composition comprising a recombinant AAV according to claim 16 and a biologically compatible solution.

22. The composition according to claim 21, wherein said composition comprises at least 10^9 particles rAAV.

REMARKS

Claims 7 and 16-22 are pending. New claims 16-22 have been added.

Claim 16 is supported on page 11, lines 12-15, page 12, line 5 and Example 7. Claim 17 is supported on page 13, lines 30-34. Claims 18 and 19 are supported on page 13, lines 3-4. Claim 20 is supported on page 13, line 7-10. Claim 21 is supported on page 15, line 28. Claim 22 is supported on page 16, line 25.

No new matter is added by this amendment.